Estados Unidos - inglês - NLM (National Library of Medicine)

newmarket health products llc - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm), menthol (unii: l7t10eip3a) (menthol - unii:l7t10eip3a) - capsaicin 2 mg in 1 g - purpose topical analgesic topical analgesic uses  for temporary relief of minor aches and pains of muscles and joints associated with: - simple backache - arthritis - strains - bruises - sprains

Estados Unidos - inglês - NLM (National Library of Medicine)

tmig, inc. - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm) - capsaicin 0.025 g in 100 g - capsaicin cream 0.025% ranitidine tablet usp 150mg diclofenac sodium tablet 75mg

Estados Unidos - inglês - NLM (National Library of Medicine)

lumiera health inc. - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm) - capsaicin 0.025%                                 topical analgesic temporarily relieves aches and pains of muscles and joints associated with: simple backache – lumbago – strains – sprains - arthritis

Estados Unidos - inglês - NLM (National Library of Medicine)

nationwide pharmaceutical llc - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm) - topical analgesic temporarily relieves minor pain associated with: - arthritis - simple backache - muscle strains - sprains - bruises

Estados Unidos - inglês - NLM (National Library of Medicine)

a2a integrated pharmaceuticals, llc - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm) - external analgesic temporarily relieves minor aches and pains of muscles and joints due to - simple backache - arthritis - strains - sprains

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - capsaicin - cutaneous cream - 250microgram/1gram

Estados Unidos - inglês - NLM (National Library of Medicine)

averitas pharma inc - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm) - qutenza is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (phn) and for neuropathic pain associated with diabetic peripheral neuropathy (dpn) of the feet. none. risk summary capsaicin is negligibly absorbed systemically following topical administration of qutenza, and maternal use is not expected to result in the fetal exposure to qutenza. in animal reproductive studies, no evidence of malformations were observed when capsaicin was administered daily by the topical route to pregnant rats and rabbits during the period of organogenesis at doses of up to 11- and 37-times, respectively, the maximum recommended human dose (mrhd) of qutenza at 716 mg capsaicin per day (4 topical systems containing 179 mg/topical systems). in a peri- and postnatal development study, no adverse effects were observed when capsaicin was administered daily by the topical route to rats during implantation to weaning at doses of up to 11-times the mrhd (see data) . the estimated backgro

Estados Unidos - inglês - NLM (National Library of Medicine)

strand health group - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm), lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - trubrexa tm transdermal patch is indicated in adults over the age of 12 years old for the treatment of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more. trubrexa tm transdermal patch is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product. 7.1 pregnancy trubrexa tm transdermal patch has not been studied in pregnancy. maternal use is not expected to result in fetal exposure. animal studies have shown no adverse effects when lidocaine and capsaicin are administered and absorbed. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, trubrexa tm transdermal patch should only be used during pregnancy if clearly needed or advised by a healthcare professional. all pregnancies have a background risk of birth d

Estados Unidos - inglês - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm), lidocaine (unii: 98pi200987) (lidocaine - unii:98pi200987) - trubrexa tm transdermal patch is indicated in adults over the age of 12 years old for the treatment of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more. trubrexa tm transdermal patch is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product. 7.1 pregnancy trubrexa tm transdermal patch has not been studied in pregnancy. maternal use is not expected to result in fetal exposure. animal studies have shown no adverse effects when lidocaine and capsaicin are administered and absorbed. there are, however, no adequate and well-controlled studies in pregnant women. because animal reproduction studies are not always predictive of human response, trubrexa tm transdermal patch should only be used during pregnancy if clearly needed or advised by a healthcare professional. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. 7.2 lactation trubrexa tm transdermal patch has not been studied in nursing mothers. lidocaine is excreted in human milk, and the milk:plasma ration of lidocaine is 0.4. capsaicin is negligibly absorbed systemically by the mother following topical administration of trubrexa tm transdermal patch. caution should be exercised when trubrexa tm transdermal patch is administered to a nursing woman. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for trubrexa tm transdermal patch and any potential adverse effects on the breastfed infant. 7.3 pediatric use safety and effectiveness in pediatric patients under the age of 12 have not been studied or established. 7.4 geriatric use safety and effectiveness are similar in geriatric patients and younger patients. no dose adjustments are required in geriatric patients.

Estados Unidos - inglês - NLM (National Library of Medicine)

hpi health products inc. - capsaicin (unii: s07o44r1zm) (capsaicin - unii:s07o44r1zm), menthol, unspecified form (unii: l7t10eip3a) (menthol, unspecified form - unii:l7t10eip3a) - capsaicin 0.35 mg in 1 ml - temporary relief of minor aches and pains of muscles and joints associated with: - simple backache - arthritis - bruises - strains - sprains